novo nordisk's semaglutide Company of the Year 2024: Nordisk – Continuing triumph Novo Nordisk 2022: Expanding capabilities

The program includes weekly check-ins to monitor your progress and adjust the plan as needed

Clinical research continues to highlight how foundational behaviourssuch as increasing soluble and prebiotic fibres, prioritising protein at meals, including healthy fats, supporting a diverse microbiome, moving regularly and protecting sleepoperate synergistically to influence GLP-1 secretion and sensitivity

Consistent high-quality sleep will help to balance your hunger hormones and balance blood sugar levels making cravings easier to manage

Semaglutide is a specific type of incretin-based medication known as a GLP-1 analogue

The two terms point to the same research compound